Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 11/20 | 0.44 |
| ▸ | MTOR | P42345 | 11/20 | 0.44 |
| ▸ | BMI1 | P35226 | 7/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 9/20 | 0.42 |
| ▸ | PIK3CB | P42338 | 9/20 | 0.42 |
| ▸ | PIK3CG | P48736 | 9/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | DHFR | P00374 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16748419 | 0.90 | PIK3CA (0.45) | PIK3CAMTORBMI1PIK3CDPIK3CB | |
| SCHEMBL16748446 | 0.88 | NPC1 (0.37) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL16740714 | 0.86 | BMI1 (0.50) | PIK3CAMTORBMI1PIK3CDPIK3CB | |
| SCHEMBL15741362 | 0.86 | BMI1 (0.42) | PIK3CAMTORBMI1PIK3CDPIK3CB | |
| SCHEMBL16740761 | 0.84 | BMI1 (0.49) | PIK3CAMTORBMI1PIK3CDPIK3CB | |
| SCHEMBL16748425 | 0.84 | MAPK1 (0.36) | BMI1DHFR | |
| SCHEMBL16740798 | 0.84 | BMI1 (0.60) | PIK3CAMTORBMI1PIK3CDPIK3CB | |
| SCHEMBL16740833 | 0.83 | PIK3CA (0.52) | PIK3CAMTORBMI1PIK3CDPIK3CB | |
| SCHEMBL16740874 | 0.82 | BMI1 (0.50) | PIK3CAMTORBMI1PIK3CDPIK3CB | |
| SCHEMBL16740765 | 0.81 | BMI1 (0.63) | PIK3CAMTORBMI1PIK3CDPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9975878-B2 | Substituted triazine BMI-1 inhibitors | PTC THERAPEUTICS, INC. (US) | 2018-05-22 | — | — | US | claimed |
| US-20160297798-A1 | SUBSTITUTED TRIAZINE BMI-1 INHIBITORS | PTC THERAPEUTICS, INC. | 2016-10-13 | — | — | US | claimed |
| US-9975878-B2 | Substituted triazine BMI-1 inhibitors | PTC THERAPEUTICS, INC. (US) | 2018-05-22 | — | — | US | disclosed |
| US-9975878-B2 | Substituted triazine BMI-1 inhibitors | PTC THERAPEUTICS, INC. (US) | 2018-05-22 | — | — | US | disclosed |
| US-9975878-B2 | Substituted triazine BMI-1 inhibitors | PTC THERAPEUTICS, INC. (US) | 2018-05-22 | — | — | US | disclosed |
| US-20160297798-A1 | SUBSTITUTED TRIAZINE BMI-1 INHIBITORS | PTC THERAPEUTICS, INC. | 2016-10-13 | — | — | US | disclosed |
| US-20160297798-A1 | SUBSTITUTED TRIAZINE BMI-1 INHIBITORS | PTC THERAPEUTICS, INC. | 2016-10-13 | — | — | US | disclosed |
| US-20160297798-A1 | SUBSTITUTED TRIAZINE BMI-1 INHIBITORS | PTC THERAPEUTICS, INC. | 2016-10-13 | — | — | US | disclosed |
| WO-2015076801-A1 | SUBSTITUTED TRIAZINE BMI-1 INHIBITORS | PTC THERAPEUTICS, INC. (US) | 2015-05-28 | — | — | WO | disclosed |
| WO-2015076801-A1 | SUBSTITUTED TRIAZINE BMI-1 INHIBITORS | PTC THERAPEUTICS, INC. (US) | 2015-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160297798-A1 | SUBSTITUTED TRIAZINE BMI-1 INHIBITORS | BMI1, BAZ2A, BAZ2B | PIK3CA 3534/4885MTOR 3440/4885BMI1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.